Ulobetasol
- Generic Name
- Ulobetasol
- Brand Names
- Bryhali, Duobrii, Lexette, Ultravate, Ultravate X Ointment
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClF2O4
- CAS Number
- 98651-66-2
- Unique Ingredient Identifier
- 9P6159HM7T
- Background
Ulobetasol is a highly potent corticosteroid. It is structurally related to clobetasol. Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Ulobetasol was granted FDA approval on 17 December 1990.
- Indication
Ulobetasol cream and ointment are indicated in the treatment of inflammatory and pruritic corticosteroid responsive dermatoses. Ulobetasol lotion is indicated in the treatment of plaque psoriasis.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
- Conditions
- PsoriasisPlaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01610596
- Locations
- 🇺🇸
Minnesota Clinical Study Center, Fridley, Minnesota, United States
🇺🇸DermResearch, Inc., Austin, Texas, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: Placebo Ointment
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2011-07-28
- Lead Sponsor
- Patel, Rita Vikram, M.D.
- Target Recruit Count
- 10
- Registration Number
- NCT01404338
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Therapeutics, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01166646
- Locations
- 🇺🇸
DermResearch Inc., Austin, Texas, United States
🇺🇸Michigan Center for Skin Care Research (dba Skin Care Research), Clinton Township, Michigan, United States
🇺🇸Somerset Skin Centre, Troy, Michigan, United States
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
- Conditions
- Stable Plaque Psoriasis
- Interventions
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT00990561
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00865267
- Locations
- 🇺🇸
DermTech International, San Diego, California, United States
Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00865605
- Locations
- 🇺🇸
DermTech International, San Diego, California, United States
Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 76
- Registration Number
- NCT00802958
Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00803166
Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 140
- Registration Number
- NCT00715975
- Locations
- 🇧🇷
Lal Clinica, Valinhos, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.